Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed with results

Key Signals

2 with results

Data Visualizations

Phase Distribution

3Total
P 1 (1)
P 2 (1)
P 3 (1)

Trial Status

Active Not Recruiting2
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT04665739Phase 2Recruiting

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

NCT03375320Phase 3Active Not Recruiting

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NCT02589522Phase 1Active Not RecruitingPrimary

Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

Showing all 3 trials

Research Network

Activity Timeline